表紙：慢性閉塞性肺疾患治療薬の市場規模・シェア・成長分析 (COPDの種類別、薬剤クラス別、投与経路別、患者属性別、流通チャネル別、地域別)：産業予測 (2025～2032年)

市場調査レポート

商品コード

1758554

慢性閉塞性肺疾患治療薬の市場規模・シェア・成長分析 (COPDの種類別、薬剤クラス別、投与経路別、患者属性別、流通チャネル別、地域別)：産業予測 (2025～2032年)

Chronic Obstructive Pulmonary Disease Drugs Market Size, Share, and Growth Analysis, By COPD Type, By Drug Class, By Administration Type, By Patient Demographics, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日: 2025年06月21日
発行: SkyQuest
ページ情報: 英文 192 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 772,793円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 904,022円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,035,251円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.81円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界の慢性閉塞性肺疾患治療薬の市場規模は2023年に75億米ドルと評価され、2024年の79億5,000万米ドルから2032年には126億7,000万米ドルに成長し、予測期間中（2025-2032年）のCAGRは6.0％で成長する見通しです。

世界の慢性閉塞性肺疾患（COPD）治療薬市場は、認知度の向上、疾患有病率の上昇、早期診断と治療への注目の高まりにより、大きな成長を遂げています。COPDは、主にタバコの煙や大気汚染などの要因によって引き起こされる進行性の呼吸器疾患であり、特に都市部や開発途上国で急増しています。その結果、肺機能を強化し症状を管理する効果的な医薬品に対する需要が高まり、入院率の低下に寄与しています。革新的な併用療法や高度な吸入技術が支持を集め、市場の拡大にさらに拍車をかけています。さらに、早期発見と意識向上を促進する公衆衛生上の取り組みや、支援政策がこの市場を牽引しています。医療システムが慢性疾患の管理を優先する中、COPD治療薬市場は呼吸器治療薬の中でも重要なセグメントであり続けています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情勢

上位5社の比較
主要企業の市場ポジショニング (2024年)
主要企業が採用した戦略
市場の近年の動向
主要企業の市場シェア (2024年)
主要企業のプロファイル
- 企業概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の対前年比較 (2022～2024年)

主要企業のプロファイル

AstraZeneca Plc
Boehringer Ingelheim International GmbH
Cadila Pharmaceuticals Ltd.
CHIESI Farmaceutici SpA
Cipla Inc.
Exela Pharma Sciences LLC
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
Innoviva, Inc.
Lupin Ltd.
Merck and Co. Inc.
Mundipharma International Ltd.
Novartis AG
Philip Morris International Inc.
SHIONOGI Co. Ltd.
Sumitomo Pharma Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Theravance Biopharma Inc.
Vertex Pharmaceuticals Inc.
Viatris Inc.

結論と提言

Product Code: SQMIG35I2384

Global Chronic Obstructive Pulmonary Disease Drugs Market size was valued at USD 7.5 billion in 2023 and is poised to grow from USD 7.95 billion in 2024 to USD 12.67 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The global chronic obstructive pulmonary disease (COPD) drugs market is experiencing significant growth due to increasing awareness, rising disease prevalence, and a heightened focus on early diagnosis and treatment. COPD, a progressive respiratory condition primarily caused by factors such as cigarette smoke and air pollution, is escalating, particularly in urban areas and developing nations. As a result, the demand for effective pharmaceuticals that enhance lung function and manage symptoms is growing, contributing to reduced hospitalization rates. Innovative combination therapies and advanced inhalation technologies are gaining traction, further fueling market expansion. Additionally, public health initiatives promoting early detection and awareness, alongside supportive policies, are driving this market. As healthcare systems prioritize chronic disease management, the COPD drugs market remains a critical segment within respiratory therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Obstructive Pulmonary Disease Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chronic Obstructive Pulmonary Disease Drugs Market Segments Analysis

Global Chronic Obstructive Pulmonary Disease Drugs Market is segmented by COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel and region. Based on COPD Type, the market is segmented into Chronic Bronchitis and Emphysema. Based on Drug Class, the market is segmented into Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics and Others. Based on Administration Type, the market is segmented into Inhalation Devices, Oral Medications and Injectable Formulations. Based on Patient Demographics, the market is segmented into Age, Gender and Disease Severity. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Chronic Obstructive Pulmonary Disease Drugs Market

The global market for chronic obstructive pulmonary disease (COPD) drugs is significantly influenced by the increasing prevalence of the condition, which affected approximately 212.3 million individuals worldwide in 2019 and resulted in 3.3 million deaths. In the United States, 6.6% of adults were diagnosed with COPD in 2018. The growing awareness of this disease, coupled with initiatives such as COPD Awareness Month, is anticipated to propel market growth by fostering early diagnosis and advancing treatment options. These efforts aim to enhance patients' quality of life, thereby driving demand for effective COPD medications globally.

Restraints in the Global Chronic Obstructive Pulmonary Disease Drugs Market

The global market for chronic obstructive pulmonary disease (COPD) drugs faces significant challenges due to various side effects associated with these medications. Adverse effects such as oral infections, bruising, and hoarseness can deter patient adherence and impede overall market growth. Although inhaled steroids, including Fluticasone, are effective in reducing the frequency of exacerbations, they can also heighten the risk of infections. Moreover, COPD drugs may lead to severe complications, such as depression, cardiovascular problems, pulmonary hypertension, and, in certain instances, lung cancer, which negatively affects patient outcomes and poses additional barriers for manufacturers in this sector.

Market Trends of the Global Chronic Obstructive Pulmonary Disease Drugs Market

The Global Chronic Obstructive Pulmonary Disease (COPD) Drugs market is witnessing a significant trend towards the emergence of biologics and personalized medicine. Innovative therapies like AstraZeneca's Fasenra are revolutionizing treatment approaches by precisely targeting the inflammation associated with COPD, thereby enhancing patient outcomes. This trend reflects a broader shift towards precision medicine, where treatments are tailored to individual patient profiles, reducing systemic side effects and improving efficacy. As awareness of COPD increases and the demand for effective management options rises, the integration of biologic therapies is expected to drive market growth and reshape therapeutic strategies globally in the coming years.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Chronic Obstructive Pulmonary Disease Drugs Market Size by COPD Type & CAGR (2025-2032)

Market Overview
Chronic Bronchitis
Emphysema

Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Combination Therapy
Bronchodilators
Corticosteroids
Phosphodiesterase Type 4 Inhibitor
Mucokinetics
Others

Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Administration Type & CAGR (2025-2032)

Market Overview
Inhalation Devices
Oral Medications
Injectable Formulations

Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Patient Demographics & CAGR (2025-2032)

Market Overview
Age
Gender
Disease Severity

Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Chronic Obstructive Pulmonary Disease Drugs Market Size & CAGR (2025-2032)

North America (COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel)
- US
- Canada
Europe (COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

AstraZeneca Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cadila Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CHIESI Farmaceutici SpA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exela Pharma Sciences LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Innoviva, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck and Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mundipharma International Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Philip Morris International Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SHIONOGI Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sumitomo Pharma Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theravance Biopharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

慢性閉塞性肺疾患治療薬の市場規模・シェア・成長分析 (COPDの種類別、薬剤クラス別、投与経路別、患者属性別、流通チャネル別、地域別)：産業予測 (2025～2032年)

Chronic Obstructive Pulmonary Disease Drugs Market Size, Share, and Growth Analysis, By COPD Type, By Drug Class, By Administration Type, By Patient Demographics, By Distribution Channel, By Region - Industry Forecast 2025-2032

目次

イントロダクション

分析手法

エグゼクティブサマリー

市場力学と展望

市場の主な考察

世界の慢性閉塞性肺疾患治療薬の市場規模・CAGR：COPDの種類別 (2025～2032年)

世界の慢性閉塞性肺疾患治療薬の市場規模・CAGR：薬剤クラス別 (2025～2032年)

世界の慢性閉塞性肺疾患治療薬の市場規模・CAGR：投与方法別 (2025～2032年)

世界の慢性閉塞性肺疾患治療薬の市場規模・CAGR：患者属性別 (2025～2032年)

世界の慢性閉塞性肺疾患治療薬の市場規模・CAGR：流通チャネル別 (2025～2032年)

世界の慢性閉塞性肺疾患治療薬の市場規模・CAGR (2025～2032年)